Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Aquestive Therapeutics

NASDAQ AQST
$5.42 0.36 7.11%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 33.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
276.94M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
242.60M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.82
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
95.50M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
52.25 %

Upcoming events Aquestive Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Aquestive Therapeutics

Stock analysis Aquestive Therapeutics

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-5.11 -1.50
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-5.13 1.38
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-7.38 -0.54
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.04 0.35
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
89.02 -27.86

Price change Aquestive Therapeutics per year

2.22$ 5.66$
Min Max

Summary analysis Aquestive Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Aquestive Therapeutics

Revenue and net income Aquestive Therapeutics

All parameters

About company Aquestive Therapeutics

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Address:
30 Technology Drive, Warren, NJ, United States, 07059
Company name: Aquestive Therapeutics
Issuer ticker: AQST
ISIN: US03843E1047
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-07-25
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.aquestive.com